Dr. Bardia on the Efficacy Results of the EMERALD Trial in ER+/HER2- Breast Cancer

Video

Aditya Bardia, MD, MPH, discusses the efficacy results of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative metastatic breast cancer.

Aditya Bardia, MD, MPH, assistant professor of medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses the efficacy results of the phase 3 EMERALD trial (NCT03778931) in estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.

The results of the EMERALD trial, which were presented during the 2021 San Antonio Breast Cancer Symposium, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with the oral selective estrogen receptor degrader (SERD) elacestrant vs standard of care (SOC) endocrine therapy in patients with ER-positive, HER2-negative advanced or metastatic breast cancer. Moreover, the agent led to a 30% reduction in the risk of progression or death vs SOC in all patients evaluated and a 45% reduction in the risk of progression or death vs SOC in patients harboring ESR1 mutations.

Higher PFS rates were observed at 6 and 12 months with elacestrant vs SOC, Bardia explains.

Ultimately, these results underscore the utility of oral SERDs vs endocrine therapy in patients with endocrine-sensitive breast cancer or tumors that are dependent on the ER pathway, Bardia concludes.

Related Videos
Michael Iglesia, MD, PhD
Jean L. Koff, MD, MS
Rohan Garje, MD
Nan Chen, MD
Sundar Jagannath, MBBS
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Debu Tripathy, MD
Changchun Deng, MD, PhD
Joaquim Bellmunt, MD, PhD